

*Language:* English

*Symposium fees:*

AFPT-Le Club Phase 1 member fees  
(2019 membership): **200 €**

Non-member fees: **300 €**

Academic student: **150 €**

*Registration:*

Required before: **March 15, 2019**

Registration form online on:

<https://clubphase1.com>

<https://www.linscription.com/activite.php?P1=15722>

**Limited number of seats!**

If you have any questions, please  
email us at [leclubphase1@gmail.com](mailto:leclubphase1@gmail.com)

*Location:*

Maison de la Chimie  
28, rue Saint Dominique  
75007 PARIS - France  
Phone : (+33)1 40 62 27 00



*Access:*

RER: Line C, Invalides Station  
Subway: Lines 8, 12 et 13, Assemblée  
Nationale, Solférino or Invalides Stations  
Bus: Lines 63, 69, 73, 83, 84 and 94



*Suggested accommodations:*

Saint Dominique Hotel  
62, rue Saint Dominique

Best Western Tour Eiffel Invalides  
35, boulevard de la Tour Maubourg

Hôtel de Varenne  
44, rue de Bourgogne

Booking directly with the hotel

AFPT – Le Club Phase I (Association by law 1901)  
is a founding member of 



*with the support of*



&



*present*

**PBPK SYMPOSIUM 2019**

**PARIS - APRIL 4, 2019**

*ACT 3*

*Physiologically Based  
Pharmacokinetic modelling (PBPK):  
A new Paradigm in Drug Development*

*sponsored by*  **GENOPOLE**  
VIVRE L'INNOVATION

# PROGRAM

## SESSION 1: Diverse Clinical Development Applications in Big Pharma

*Chairs: Henri Caplain (AFPT - Le Club Phase 1) -  
Jean-Louis Pinquier (AFPT - Le Club Phase 1)*

- 8:30 AM Welcome coffee/tea
- 9:00 AM Mechanistic Oral Absorption Modelling  
an update on cross-industry activities  
Neil Parrott,  
Modelling & Simulation Scientist,  
Roche Innovation Center Basel
- 9:40 AM Developmental changes in drug  
disposition and responses: the challenges  
Jean-Marie Nicolas,  
Director PK/PD, Development Science Dpt,  
UCB Biopharma SPRL
- 10:00 AM Break
- 10:30 AM F.I.H 4 F.I.H: Faith in Holistic  
modelling for First-in-Human PK  
Neil Miller,  
DMPK Investigator-PBPK Leader,  
GSK
- 11:40 AM Physiological Based Absorption  
Modelling in industrial practice.  
Current applications  
and a vision for the future  
Xavier Pepin,  
Principal Scientist,  
Astrazeneca
- 12:00 PM Questions & Answers

## SESSION 2: Early discovery (ADMET-PBPK), UGT metabolism

*Chairs: Neil Parrott (Roche) -  
Jérémy Perrier (PhinC D.)*

- 12:05 PM Age-dependent variations in activity  
of hepatic UGT enzymes: Application  
to PBPK modelling  
Justine Badee,  
Post-doctoral Associate,  
Roche/University of Florida
- 12:45 PM Lunch
- 2:00 PM Challenges of transporter IVIVE:  
a digoxin example  
Maily De Sousa Mendes,  
PhD, Research Scientist,  
Simcyp
- 2:40 PM Discovery PBPK: Efficiently using  
machine learning & PBPK  
modeling to drive lead selection  
& optimization  
Viera Lukacova,  
Director, Simulation Sciences,  
Simulations Plus
- 3:00 PM Questions & Answers

AFPT – Le Club Phase I (Association by law 1901)  
is a founding member of 

## SESSION 3: PBPK in special populations: Pediatric and pregnancy models

*Chairs: Florence GATTACCECA (Aix-Marseille  
Université) - Benjamin Dupont (PhinC D.)*

- 3:05 PM Analysis of UGT activity changes  
during pregnancy through PBPK  
modeling  
Andre Dallmann,  
Scientist Systems Pharmacology,  
Bayer
- 3:45 PM Paediatric and Pregnancy PBPK/PD  
Modelling: Clinical and Drug  
Development Applications  
Trevor Johnson,  
Principal Scientist,  
Simcyp
- 4:25 PM Break
- SESSION 4:  
What's new for regulatory  
requirements?
- 4:45 PM The finalised EMA guideline and  
latest experience of PBPK models  
in Regulatory submissions  
Paola Coppola,  
MHRA
- 5:25 PM Questions & Answers
- 5:30 PM Closing Remarks